SAN
FRANCISCO, Aug. 20, 2024 /PRNewswire/
-- Schubert Jonckheer & Kolbe LLP advises Ocugen, Inc.
investors that the firm is investigating potential legal claims
relating to an earnings restatement and possible substantial
insider trading by key executives and company directors. Current
shareholders are encouraged to contact the
firm regarding their rights.
Ocugen is a clinical-stage biopharmaceutical company. On
April 1, 2024, the company announced
it was restating its financial statements going back to 2020,
resulting in a substantial decline in the stock price. The company
admitted that those financial statements had been materially
misstated. During that period, Ocugen insiders sold over
$30 million in company stock. Based
on these facts, the company has also been sued in a securities
fraud class action.
The Schubert firm is investigating potential wrongdoing by
Ocugen's officers and directors in connection with these
allegations.
If you own stock in Ocugen and want additional information
about your legal rights, please visit our website at
https://www.classactionlawyers.com/ocugen.
About Schubert Jonckheer & Kolbe LLP
Schubert Jonckheer & Kolbe represents shareholders,
employees, and consumers in class actions against corporate
defendants, as well as shareholders in derivative actions against
their officers and directors. The firm is based in San Francisco, and with the help of
co-counsel, litigates cases nationwide.
Contact
Dustin L.
Schubert
Schubert Jonckheer & Kolbe LLP
dschubert@schubertlawfirm.com
Tel: (415) 788-4220
View original
content:https://www.prnewswire.com/news-releases/ocugen-inc-investor-alert-nasdaq-ocgn-schubert-jonckheer--kolbe-llp-investigating-potential-claims-against-the-companys-officers-and-directors-following-earnings-restatement-and-possible-insider-trading-302226055.html
SOURCE Schubert Jonckheer & Kolbe LLP